Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects
Clinical Pharmacology in Drug Development · 2023-11 · 12 (11) · 1114-1120
DOI: 10.1002/cpdd.1302 ↗At a glance
Randomisierte kontrollierte Studie in Clinical Pharmacology in Drug Development, published online on 2023-08-04. Written by Devki D Sukhtankar and 4 co-authors. Institution: GPCR Therapeutics, Inc., Seoul, South Korea. Major MEDLINE topics: Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cell Transplantation. Cited 9 times so far (Crossref); 5 references.
Abstract (original language)
Adequate mobilization of hematopoietic stem cells (HSCs), especially CD34 + cells, is necessary for stem cell transplantation in patients with hematological malignancies or autoimmune diseases. Burixafor is an inhibitor of the C‐X‐C Chemokine Receptor 4 that disrupts the C‐X‐C motif chemokine 12 (CXCL12)/CXCR4 axis in the bone marrow, releasing HSCs into circulation. In mice, a single intravenous dose of burixafor was rapidly absorbed (time to maximum concentration, 5 minutes) and increased peripheral white blood cell counts within 30 minutes. Additionally, burixafor was administered to 64 healthy subjects in a randomized, double‐blind, placebo‐controlled, single‐ascending‐dose study to evaluate safety, pharmacokinetics, and pharmacodynamics. Subjects received burixafor intravenous doses ranging from 0.10 to 4.40 mg/kg in 8 cohorts. Single doses were generally safe and well tolerated. Gastrointestinal events were reported at doses of 2.24 mg/kg or greater. Exposure (maximum concentration and area under the concentration–time curve) increased in an approximately dose‐proportional manner. Time to maximum concentration occurred with a median of 0.26–0.30 hours that was not dose proportional. As expected, white blood cell, CD133 + cell, and CD34 + cell concentrations generally increased with the increases in burixafor dose from 0.10 to 3.14 mg/kg. At maximal levels, the CD34 + cell counts increased 3‐ to 14‐fold from baseline levels. These results provide support for continued clinical development of burixafor.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- GPCR Therapeutics, Inc., Seoul, South Korea.
- GPCR Therapeutics USA, Redwood City, CA, USA.
- TaiGen Biotechnology Col Ltd, Taipei, Taiwan.
Cite
APA
Sukhtankar, D. D., Chang, L. W., Tsai, C. Y., Cardarelli, P. M., & Caculitan, N. G. (2023). Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects. Clinical Pharmacology in Drug Development, 12(11), 1114-1120. https://doi.org/10.1002/cpdd.1302
Vancouver
Sukhtankar DD, Chang LW, Tsai CY, Cardarelli PM, Caculitan NG. Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects. Clinical Pharmacology in Drug Development. 2023;12(11):1114-1120. doi:10.1002/cpdd.1302
BibTeX
@article{Sukhtankar2023,
author = {Sukhtankar, Devki D and Chang, Li-Wen and Tsai, Cheng-Yuan and Cardarelli, Pina M and Caculitan, Niña G},
title = {Pharmacokinetics and Pharmacodynamics of Burixafor Hydrobromide (GPC‐100), a Novel C‐X‐C Chemokine Receptor 4 Antagonist and Mobilizer of Hematopoietic Stem/Progenitor Cells, in Mice and Healthy Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
volume = {12},
number = {11},
pages = {1114--1120},
doi = {10.1002/cpdd.1302}
}
EUVIMED